Sitemap
Pages
- About Us
- Careers
- Contact
- DATA SUBJECT REQUEST FORM
- Home
- Imkeldi Ordering
- JYLAMVO Ordering
- JYLAMVO Patient Access
- JYLAMVO Patient Instructions
- News
- News
- Patient Access
- Pipeline
- Privacy Policy
- Sitemap
- Tablets
- TEPYLUTE Ordering
- Test Popup
- Our Team
Posts by category
- Category: Company Updates
- Shorla Oncology Receives FDA Approval for Larger Nelarabine Vial
- Shorla Oncology at the 2025 Jefferies Global Healthcare Conference
- Shorla Oncology Proud to Attend the NCODA International fall summit
- Shorla Oncology Proud to be a Sponsor at the OneOncology Annual Conference
- Shorla Oncology Proud to Participate at FCS 2025 Clinical Summit
- Shorla Oncology Exhibits AT THE 49th Annual APHON Conference
- Shorla Oncology Attends Children Oncology Group Meeting
- Shorla Oncology Proud to Attend the NCODA Oncology Institute Meeting
- SH-110 Receives FDA Orphan Drug Designation for Rare Brain Cancer
- Shorla Oncology Attends ATOPP Summit 2025
- Shorla Oncology Attends 2025 Cardinal Health™ NOC
- Shorla Co-Founders – EY Entrepreneur of the Year 2025 Finalists
- Shorla Oncology Participates in ASCO 2025
- Shorla Receives Great Place to Work Certification 2025
- FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG
- Shorla Oncology is attending AXS25 SUMMIT April 27 – May 1, 2025
- Shorla Oncology is attending the PCMA Annual Meeting March 10-11 2025
- Audrene Rice, Our R&D Pipeline and Portfolio Manager, is attending Bio-Europe from March 17-19 in Milan, Italy
- Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
- We are delighted to be recognised as a Best Workplace by Great Place to Work
- Sharon and Orlaith were recently awarded the Irish Times Future Leaders award
- We are attending the JP Morgan Healthcare Conference 2025 in San Francisco January 13-16. We look forward to meeting you there.
- Shorla Oncology co-founders win EY Entrepreneurs of the Year award
- Shorla Oncology Announces FDA Approval of IMKELDI (imatinib mesylate)
- Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
- Shorla Oncology will be attending The (ACR) Convergence 2024 in Washington DC from Nov 14-19
- Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12
- Frontiers Health 2024
- Shorla Oncology at CPHI Milan
- Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer
- Enterprise Ireland Start-up Day 2024
- SHORLA ONCOLOGY TO ATTEND ASEMBIA24
- MassBio | SHARON CUNNINGHAM
- Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year Finalists
- Scaling Your Business Panel Participation
- InterTrade Ireland All Island Venture Capital Conference
- Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers
- We are delighted to be attending the HOPA 2024 conference at Tampa Florida from 3-6 April. We are looking forward to meeting you at Booth #620.
- Shorla Oncology Achieves Great Place to Work Certification
- Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancer
- Shorla Oncology attending JP Morgan Healthcare Conference
- Press Release: Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer
- Shorla Oncology at ASH Annual Meeting and Exposition
- Shorla Oncology attending Jefferies Healthcare Conference
- PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind
- Shorla Oncology at BIO-Europe 2023
- Shorla Oncology at CPhI Barcelona 2023
- PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio
- Shorla Oncology at LSX USA Congress
- Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States
- 100k in 30 days for breast cancer
- Mid-West Building Better Business event
- Shorla Oncology at BioEquity Europe 2023 in Dublin
- Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection
- Step Challenge for Oscars Kids!
- Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas
- Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023
- Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia
- We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!
- Join Shorla Oncology at the BIO CEO and Investor Conference 2023
- Join Shorla Oncology at the Biotech Showcase 2023
- Our CEO part of the “Cancer Across Borders – Ireland’s Reach” Panel Discussion
- Join Shorla Oncology at CPhI Frankfurt 2022
- Shorla Oncology at Bio Europe 2022
- Our CTO spoke on the founders panel at Scale Ireland’s Annual Event
- Our CEO spoke at the LSX World Congress USA in Boston
- Shorla Oncology at ASCO Annual Meeting, Chicago 2022
- Our CCO, Nicholas Holsman speaks at the MassBio Conference
- Shorla Oncology Appoints Dennis Purcell as Chairman
- Company Name Change: Shorla Pharma is now Shorla Oncology!
- Shorla Oncology at Bio CEO & Investor conference, New York 2022
- Shorla Oncology at Euronext IPO ready programme, Dublin 2022
- Shorla Oncology at ASH, Atlanta, Georgia 2021
- CEO Sharon Cunningham met with Minister Robert Troy at Enterprise Ireland’s trade visit in Boston
- Shorla Oncology at CPhI Worldwide in Milan
- Shorla Oncology at Asembia Specialty Pharmacy Summit
- Shorla recently welcomed the Minister of State for Business, Employment and Retail, Damien English to the Clonmel office
- Shorla Oncology at HLTH Boston 2021
- Shorla Oncology at Biotech Week Boston
- Reuters Global Pharma Awards – Finalist
- Shorla Oncology Announces Partnership with EVERSANA
- Shorla Oncology Expands into the U.S.
- Team Shorla Oncology complete 100k in 30 days for Breast Cancer
- FDA filing acceptance and priority review received for SH-111
- United Conference of Generics, Vaccines and Biosimilars
- 30 % Club Ireland
- Shorla Oncology Announces Chief Commercial Officer
- Shorla Oncology – Q&A with Tracy Woody
- John Moloney and Tracy Woody announced as non-executive Board members
- Shorla speak with Dr. Scott Gottlieb, 23rd FDA Commissioner
- SH-110 Successful FDA Pre-IND Meeting
- Shorla Oncology named Local Enterprise of the Year at The Irish Times Business Awards 2020
- Shorla Oncology closes $8.3M Series A funding round
- Manufacture of first GMP batch of SH-111
- University City Science Center Bootcamp, Philadelphia, USA
- Worldwide Association of MBA’s Best Entrepreneurial Venture Award (Private Sector) 2020
- J.P. Morgan Annual Healthcare Conference, San Francisco, USA
- Sharon and Orlaith featured in the Irish Times Top 50 people to watch in 2020
- SodEXo Women Mean Business (WMB) Female Newcomer Award 2019
- SH-111 Successful FDA pre-IND meeting
- Shorla Oncology featuring in Enterprise Ireland and the Local Enterprise Offices ‘Start’ campaign
- Ireland’s Best Young Entrepreneur 2019
- SH-105 Successful FDA pre-IND meeting
- American Society of Clinical Oncologists (ASCO) Annual Meeting 2019, Chicago, USA
- Network Ireland Tipperary Businesswoman of the year – Emerging New Business AWARD 2019
- Shorla attending MIT-Harvard Medical School Healthcare Innovation Bootcamp, Boston, USA
- Shorla Oncology meet Nancy Pelosi, Madam Speaker of the US House of Representatives
- DCAT New York City, USA
- Biotech Showcase at J.P. Morgan Annual Healthcare Conference, San Francisco, USA
- Shorla Oncology attend Harvard Business School 19th annual Healthcare conference, Boston, USA
- Shorla Oncology visit North Carolina Research Triangle, USA
- Shorla Oncology at SelectUSA Investment Summit, Washington, USA
- Shorla Oncology attending CPhI North America, Philadelphia, USA
- Category: Events
- Category: Media
- FDA OKs Nelarabine Larger Vial Size for T-ALL and T-LBL: Data and Dosing
- FDA Approves Larger Nelarabine Vial for Some Leukemias and Lymphomas
- FDA OKs Larger Nelarabine Vial in T-Cell Leukemia and Lymphoma Populations
- FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL
- FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
- SH-110 receives FDA orphan drug designation for the treatment of Glioma
- FDA Grants Orphan Status to Liquid Glioma Treatment SH-110
- FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma
- Oral Liquid for Brain Cancer Gets FDA Fast Track Designation
- FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy
- Sharon Cunningham Featured by YPO for Driving Innovation in Oncology
- FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers
- Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available
- Tepylute for breast, ovarian cancer launched in US
- Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas
- FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer
- Shorla wins FDA nod for ready-to-dilute Tepylute
- Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available
- FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG
- Shorla Oncology develops and commercializes innovative oncology drugs, where existing treatments are limited, in shortage or inadequate.
- Shorla, Protega Win Expanded Nods for Cancer/Autoimmune, Pain Therapies
- FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL
- FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia
- FDA Expands Liquid Methotrexate Indication to Pediatric ALL Patients
- Shorla is building a global Irish pharma brand
- EY Entrepreneur Of The Year
- FDA Approves Tepylute for Breast and Ovarian Cancer Treatment
- FDA approves Shorla Oncology’s TEPYLUTE for cancer treatment
- A Milestone for Shorla Oncology
- FDA Considers SH-201 for Treating Certain Leukemias and Cancers
- FDA Accepts NDA for SH-201 in Leukemia and Other Cancers
- FDA Accepts Shorla’s NDA for SH-201 to Treat Leukemia and Other Cancers
- FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer
- OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer
- Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer
- Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer
- Goodman-backed Shorla Oncology secures $35m in Series-B funding
- Shorla Oncology raises $35m to accelerate growth
- Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology
- Women Of The Year 2023 Awards Nomination
- FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma
- US FDA approves Shorla’s oncology drug for T-cell leukaemia
- Shorla wins FDA approval for leukaemia drug
- Irish-founded Shorla Oncology secures FDA approval for leukaemia drug
- Improve Oncology Drug Shortages with A More Reliable Supply Source
- Our CEO on Biocentury’s Bio€quity Europe podcast
- 3 Keys To A Successful Biotech Launch
- Shorla: making women’s and children’s cancer drugs more accessible
- PharmaVoice Women of the Week – Podcast
- Shorla Oncology scores an expedited review for its mystery candidate to treat T-cell malignancies
- Female-Founded Irish Tech Companies Raise Record €105M
- The company targeting unmet needs in oncology
- Diversity & inclusion in Pharma
- Making It Work: Irish firm to launch children’s cancer treatment in US
- Female entrepreneurs can help level the start-up playing field
- Sharon Cunningham : Six Keys to Beating the Odds and Achieving Startup Success
- How an executive MBA was the catalyst for a pharma start-up
- Women in pharma face unique obstacles: Shorla Oncology
- Shorla Oncology – 3 tips for pharma startup success
- Ireland’s Shorla nabs $8.3M for improved cancer meds to the U.S.
- Shorla Oncology Irish Pharmaceutical startup-Tipperary
- Category: Uncategorised